Virbac announce first EU canine leishmaniosis vaccine at BSAVA

After 20 years of development and stringent testing, CaniLeish has been proven effective in vaccinating dogs against leishmaniosis. Clinical trials demonstrated a 93% success rate over a two year period using realistic environmental conditions.

CaniLeish consists of three injections given over six weeks, dogs should then be vaccinated anually.

Leishmaniosis is a parasitic disease which is often fatal, causing skin lesions, hair loss, dermatitis and severe kidney failure. For full details about the disease visit Vetstream.

Canine leishmaniasis is a rapidly spreading, relatively little known disease that affects both humans and animals and can be fatal. The disease is treatable, and the purpose of these symposiums is to raise awareness both in owners and vets.

There will be another leishmaniasis symposium as part of SEVC 2011 in Madrid. Click here for full details to sign up.

Read more for the full proceedings from the Leishmaniasis Symposium in June 2011.

Read more…

Virbac (www.virbac.com) announced that the European Commission has awarded the company a European registration for CaniLeish, the first vaccine against canine leishmaniosis in Europe. CaniLeish will initially be launched in Portugal at the end of the first half of 2011; this will be followed by launches in other countries in the endemic area of southern [...]